Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Potential For Califf’s Second Term As US FDA Commissioner Surprises, Excites Stakeholders

Oct 19 2021

• By Derrick Gingery

• Source: Alamy

Related Content

Beyond Aduhelm: OIG Review Will Put FDA’s Entire Accelerated Approval Program Under Microscope

Aug 05 2021

US FDA’s Woodcock ‘Managing As If She’s Been Commissioner,’ Not Afraid To Act, CBER Director Says

Oct 13 2021

Campaign Against Woodcock’s US FDA Commissioner Bid Has Begun

Jan 29 2021

A Return Trip For Kessler At US FDA? It Wouldn’t Be The First Time It’s Happened

Dec 03 2020

FDA's Opioid Action Plan Could Clear Califf Nomination Roadblock

Feb 04 2016

Califf Nomination Suffers 'Pile On': What Can FDA Do To Break Logjam?

Feb 01 2016

Califf Has Several Industry Ties To Sever Before Joining FDA

Feb 02 2015

Sarepta's Eteplirsen Approved After Contentious Internal FDA Debate

Sep 20 2016

Political Appointees Shouldn't Influence Approval Decisions, Califf Says

Oct 20 2016

In Second Term At Helm, Would Califf Steer US FDA On Supplement Market Regulation Changes?

Oct 19 2021

Related Companies

Verily

Sarepta Therapeutics, Inc.

Biogen, Inc.

Eisai Co., Ltd.

Additional Topics

International United States FDA Leadership Politics Commercial Consumer Dietary Supplements Cosmetics OTC Drugs Policy Regulation

More from Regulation

More from Policy & Regulation

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window